Table 2.
Antiproliferative activity of TTHL on human cell lines
| IC50 (μg/mL) a ± SD | |||||||
|---|---|---|---|---|---|---|---|
| Time of Treatment (h) | Selectivity index (SI) b/superscript value | ||||||
| MRC5 | MCF-7 | HepG2 | T24 | HCT116 | HT29 | CACO-2 | |
| 24 | 8.40 ± 0.28 | 1.36 ± 0.056X | 6.50 ± 0.431.3X | 5.55 ± 0.641.5X | 7.05 ± 0.211X | 8.00 ± 0.141X | 8.55 ± 0.35MR |
| 48 | 7.60 ± 0.14 | 0.73 ± 0.0510X | 6.10 ± 0.281X | 5.20 ± 0.421.5X | 5.87 ± 0.041X | 7.00 ± 0.421X | 7.90 ± 0.28MR |
| 72 | 7.40 ± 0.15 | 0.63 ± 0.0412X | 5.45 ± 0.351X | 1.09 ± 0.147X | 5.20 ± 0.281X | 6.15 ± 0.211X | 6.35 ± 0.351X |
| 120 | 6.84 ± 0.10 | 0.30 ± 0.0423X | 0.88 ± 0.138X | 0.39 ± 0.1017X | 4.50 ± 0.291.5X | 5.30 ± 0.281X | 5.00 ± 0.191X |
| 24/MXT c | 2.88 ± 1.44 | 0.87 ± 1.59 | 3.5 ± 0.39 | 2.50 ± 0.62 | 0.61 ± 0.67 | 0.88 ± 2.33 | 2.4 ± 1.81 |
aDrug concentration required to inhibit the cell growth by 50% after 24 h of incubation. bSelectivity index (in vitro): IC50 in MRC5 cells/IC50 in tumoral cells. Data represent mean ± three separate experiments. cMitoxantrone (MXT) was used as positive control. MR: more resistant in tumoral cells.